^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | PLX51107 (BET inhibitor, MYC inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
In a murine xenograft model of AML using MV4-11 cells, PLX51107 alone induced suppression of tumor growth in association with a 90% decrease in c-Myc gene expression.
DOI:
10.1182/blood-2019-124030
